Genscript Biotech's high P/S ratio is due to its promising revenue outlook. The company's strong performance and bright future are likely to keep supporting the share price unless conditions change.
GenScript's leadership values Dr. Liu's expertise in genome editing, chemistry, and synthetic biology for its potential to offer key insights. His addition to the SAB is anticipated to boost GenScript's platform and hasten transformative breakthroughs for patients.
Dr. June joining GenScript's SAB could provide invaluable insights for their initiatives, especially in cell and gene therapy. His expertise may accelerate the development of novel therapies.
$Hang Seng Index(800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$REMEGEN-B(09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $CLOVER BIO-B(02197.HK)$nosedived 9.6% to $0.47, hitting record low.$維亜生物科技(01873.HK)$...
Despite Genscript Biotech's promising revenue outlook, its P/S ratio isn't higher than industry peers due to potential volatility in revenue forecasts. Investors should note the company's 2 warning signs.
The continuous sell-off of shares by insiders could be concerning for shareholders, as this does not reflect confidence in the company’s outlook. This activity indicates that investors may need to exercise caution when considering investment in Genscript Biotech.
Genscript Biotech, though in debt, retains substantial net cash, suggesting manageable debt. Its remarkable revenue surge last year could point to future profitability, but its presently unprofitability at the EBIT level and recent negative cash outflows suggest more capital might be needed. The overall risk for Genscript Biotech is notable at this point.
$金斯瑞生物科技(01548.HK)$ The development trend of Kingsley company is thriving, and the strength of the short market is like the vehicle on the wrong side of the lane in the rush, its outcome will be faced with a tragic situation, Monday short market to borrow shares, the results of low by Hong Kong shares to do more money to buy 1.31 million shares.
金斯瑞生物科技に関するコメント
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
Pharmaceuticals were sold off. $REMEGEN-B(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $維亜生物科技(01873.HK)$ ...
HKD191.9M Southbound Trading Net Inflow to KUAISHOU-W
There was HKD95.3 million Southbound Trading net outflow from $金斯瑞生物科技(01548.HK)$ .
For $SH->HK コネクト(GangGuTong.HK)$ , $中国移動(00941.HK)$ was the most active stock with highest net inflow of HKD205.2 million, while $華能国際電力(00902.HK)$ was the m...
HSI Slides 342 Pts; Techs & Pharmas Gloom
Techs slid as the market continued to be watchful of the Sino-US relations:
$阿里巴巴集団(09988.HK)$ dived 3.2% to $84.1.
$テンセント(00700.HK)$ sank 1.9% to $338.4.
$美団点評(03690.HK)$ , $小米集団(01810.HK)$ , ...
The development trend of Kingsley company is thriving, and the strength of the short market is like the vehicle on the wrong side of the lane in the rush, its outcome will be faced with a tragic situation, Monday short market to borrow shares, the results of low by Hong Kong shares to do more money to buy 1.31 million shares.
まだコメントはありません